Wave Life Sciences (WVE) Corporate presentation summary

Mission and platform

• Aims to unlock the broad potential of RNA medicines to transform human health.

• Utilizes a differentiated RNA medicines platform with proprietary chemistry and strong IP.

• In-house GMP manufacturing supports rapid translation of genetic insights into therapies.

• Well capitalized with cash runway expected into Q3 2028.

Pipeline overview

• Robust pipeline includes first-in-class RNAi (SpiNA) and RNA editing (AIMer) programs.

• Lead programs: WVE-007 (obesity), WVE-006 (AATD), WVE-008 (liver disease).

• Additional programs target DMD and Huntington's disease.

• Patient populations for lead indications are substantial, exceeding 1 billion globally for obesity.

WVE-007 for obesity

• Targets INHBE to induce fat loss while preserving muscle, addressing limitations of current therapies.

• Demonstrated durable, dose-dependent reductions in visceral fat and Activin E in preclinical and Phase 1 studies.

• Potential for 1-2x yearly dosing, generally safe and well tolerated.

• Phase 2a INLIGHT trial underway, with combination and maintenance studies planned.